Product-By-Process Patents In Orange Book Should Claim Novel Products – FTC
Executive Summary
FDA should ensure that product-by-process patents listed in the "Orange Book" claim only novel products, the Federal Trade Commission said in comments on FDA's proposed rule
You may also be interested in...
GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns
The generic industry should consider carefully any attempt to derail FDA's regulatory approach to Waxman/Hatch reform, agency Chief Counsel Daniel Troy told the Generic Pharmaceutical Association
GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns
The generic industry should consider carefully any attempt to derail FDA's regulatory approach to Waxman/Hatch reform, agency Chief Counsel Daniel Troy told the Generic Pharmaceutical Association
Waxman/Hatch Reinterpretation Underpins Change In 30-Month Stay Policy
FDA's proposal to allow only one 30-month stay of approval for ANDAs hinges on a reinterpretation of Waxman/Hatch language declaring that patent holders must be notified if a generic application is amended to "include" a Paragraph IV certification